Market Cap 1.68B
Revenue (ttm) 6.24M
Net Income (ttm) -84.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,361.70%
Debt to Equity Ratio 0.00
Volume 1,685,100
Avg Vol 718,294
Day's Range N/A - N/A
Shares Out 42.88M
Stochastic %K 87%
Beta 1.55
Analysts Strong Sell
Price Target $68.00

Company Profile

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinati...

Industry: Biotechnology
Sector: Healthcare
Phone: 929 999 4055
Address:
7 Times Square, 43rd Floor, New York, United States
stockanalysis_
stockanalysis_ Jan. 13 at 10:35 PM
After Hours Losers: $DNTH $HUBC $MLEC $IOTR $ATON Save this screener: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading
0 · Reply
JackDarwin
JackDarwin Jan. 8 at 12:08 PM
$DNTH Bullish Kicker Candlestick Pattern formed at downtrend.
0 · Reply
HerbivoreH
HerbivoreH Dec. 25 at 12:20 PM
$DNTH The strategic path forward will be judged on practical milestones, not narrative strength. The market is increasingly intolerant of delays that stretch credibility. Successful iteration can create optionality that is not yet fully priced. The market will respond to evidence, not speculation.
0 · Reply
RunnerSignals
RunnerSignals Dec. 23 at 9:01 PM
$HUMA $SMR $BKSY $DNTH $NRXS are on fire! Massive upside potential rockets ready to lift off https://stocksrunner.com/news/2025-12-23-stock-upgrades-today-highlight-top-picks
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 23 at 1:40 PM
$DNTH (+1.5% pre) Leads Biolabs and Dianthus begin phase 1 trial for lupus drug https://ooc.bz/l/88252
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 1:38 PM
Wedbush updates rating for Dianthus Therapeutics ( $DNTH ) to Outperform, target set at 46.
0 · Reply
NJgolfer
NJgolfer Nov. 20 at 5:29 PM
$DNTH research courtesy of Gemini: Focus: Next-generation complement inhibitor Claseprubart (an upstream C1s inhibitor). Target Market: gMG (generalized Myasthenia Gravis), CIDP, and other rare autoimmune disorders. This is a multi-billion dollar market. The Reward: Claseprubart is designed for subcutaneous, self-administered injection every two or even four weeks, potentially offering a best-in-class convenience profile over existing IV or more frequent sub-Q options. Phase 2 data suggests strong efficacy and a favorable safety profile. The Risk: It's a "Show Me" Story. The key Phase 3 trial in gMG is anticipated to initiate in 2026. While interim data for the CIDP trial is expected in Q2 2026, the major blockbuster opportunity in gMG is still years away from market. The current valuation hinges entirely on the strong Phase 2 data translating. Verdict: Keep if you believe in the superiority profile and are comfortable waiting until 2026/2027 for primary Phase 3 data.
0 · Reply
Spicy_Trade
Spicy_Trade Nov. 16 at 9:50 PM
SpicyTrade Dianthus Therapeutics, Inc. ( $DNTH ) daily stock analysis https://youtu.be/pfcBrupSE20?si=i7dGsHRhoR9XINFp
0 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 9:22 PM
Market Warriors $PGEN $DVLT $CSIQ $BE $DNTH flipped red to green with style today. Big volume sharp rebounds and even sharper questions
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 12:35 PM
HC Wainwright & Co. updates rating for Dianthus Therapeutics ( $DNTH ) to Buy, target set at 40 → 47.
0 · Reply
Latest News on DNTH
Magenta Therapeutics to Explore Strategic Alternatives

Feb 2, 2023, 4:05 PM EST - 3 years ago

Magenta Therapeutics to Explore Strategic Alternatives


stockanalysis_
stockanalysis_ Jan. 13 at 10:35 PM
After Hours Losers: $DNTH $HUBC $MLEC $IOTR $ATON Save this screener: https://stockanalysis.com/markets/afterhours/losers/?ref=saveontrading
0 · Reply
JackDarwin
JackDarwin Jan. 8 at 12:08 PM
$DNTH Bullish Kicker Candlestick Pattern formed at downtrend.
0 · Reply
HerbivoreH
HerbivoreH Dec. 25 at 12:20 PM
$DNTH The strategic path forward will be judged on practical milestones, not narrative strength. The market is increasingly intolerant of delays that stretch credibility. Successful iteration can create optionality that is not yet fully priced. The market will respond to evidence, not speculation.
0 · Reply
RunnerSignals
RunnerSignals Dec. 23 at 9:01 PM
$HUMA $SMR $BKSY $DNTH $NRXS are on fire! Massive upside potential rockets ready to lift off https://stocksrunner.com/news/2025-12-23-stock-upgrades-today-highlight-top-picks
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 23 at 1:40 PM
$DNTH (+1.5% pre) Leads Biolabs and Dianthus begin phase 1 trial for lupus drug https://ooc.bz/l/88252
0 · Reply
JarvisFlow
JarvisFlow Dec. 22 at 1:38 PM
Wedbush updates rating for Dianthus Therapeutics ( $DNTH ) to Outperform, target set at 46.
0 · Reply
NJgolfer
NJgolfer Nov. 20 at 5:29 PM
$DNTH research courtesy of Gemini: Focus: Next-generation complement inhibitor Claseprubart (an upstream C1s inhibitor). Target Market: gMG (generalized Myasthenia Gravis), CIDP, and other rare autoimmune disorders. This is a multi-billion dollar market. The Reward: Claseprubart is designed for subcutaneous, self-administered injection every two or even four weeks, potentially offering a best-in-class convenience profile over existing IV or more frequent sub-Q options. Phase 2 data suggests strong efficacy and a favorable safety profile. The Risk: It's a "Show Me" Story. The key Phase 3 trial in gMG is anticipated to initiate in 2026. While interim data for the CIDP trial is expected in Q2 2026, the major blockbuster opportunity in gMG is still years away from market. The current valuation hinges entirely on the strong Phase 2 data translating. Verdict: Keep if you believe in the superiority profile and are comfortable waiting until 2026/2027 for primary Phase 3 data.
0 · Reply
Spicy_Trade
Spicy_Trade Nov. 16 at 9:50 PM
SpicyTrade Dianthus Therapeutics, Inc. ( $DNTH ) daily stock analysis https://youtu.be/pfcBrupSE20?si=i7dGsHRhoR9XINFp
0 · Reply
RunnerSignals
RunnerSignals Nov. 14 at 9:22 PM
Market Warriors $PGEN $DVLT $CSIQ $BE $DNTH flipped red to green with style today. Big volume sharp rebounds and even sharper questions
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 12:35 PM
HC Wainwright & Co. updates rating for Dianthus Therapeutics ( $DNTH ) to Buy, target set at 40 → 47.
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 1:32 PM
Wedbush has updated their rating for Dianthus Therapeutics ( $DNTH ) to Outperform with a price target of 46.
0 · Reply
NNNTrader
NNNTrader Nov. 2 at 5:38 AM
$DNTH Small-cap biotech setting up. Insiders + institutions have ~100% of the float. 12% Short float for fuel.
0 · Reply
G101SPM
G101SPM Oct. 27 at 7:11 PM
#SHOWTIME American Association of Neuromuscular and Electrodiagnostic Medicine Meeting (October 28-30) Scheduled to appear: $ARGX, $CPRX, $DNTH, $KYTX, $VOR
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 16 at 12:44 PM
$DNTH (+0.9% pre) Dianthus Therapeutics licenses DNTH212 from Leads Biolabs https://ooc.bz/l/80760
0 · Reply
JarvisFlow
JarvisFlow Oct. 14 at 1:07 PM
Truist Securities has adjusted their stance on Dianthus Therapeutics ( $DNTH ), setting the rating to Buy with a target price of 56.
0 · Reply
Quantumup
Quantumup Oct. 14 at 10:43 AM
Truist🏁 $DNTH Buy/$56 $ARGX $AZN NVS $JNJ $IMVT CABA Truist said in its initiation report: Dianthus' differentiated approach to targeting the autoantibody mediated complement cascade (C1s inhibition), may offer similar efficacy as available complement (C5) inhibitors, but with a cleaner safety profile. The recent Ph 2 proof-of-concept (PoC) results with claseprubart in generalized myasthenia gravis (gMG) were overall supportive of this thesis. In our view, gMG data are also relatively de-risking for the ongoing Ph 3 chronic inflammatory demyelinating polyneuropathy (CIDP) trial, for which we see significant upside potential upon positive data in 2H26.
0 · Reply
Doozio
Doozio Oct. 1 at 4:17 PM
$DNTH no it won’t. Bahhht it was always 🐒🍌🧠⏰♾️ wen MLYS are becoming BILI’s.
0 · Reply
Ryder845
Ryder845 Sep. 26 at 4:08 AM
$DNTH big money on insider option trades.
0 · Reply
theflynews
theflynews Sep. 22 at 10:58 AM
Short Report: Dave & Busters bears boost exposure - $DNTH - https://thefly.com/permalinks/entry.php/DNTHid4201028?1758537978C38
0 · Reply
SuzannaMcclung593
SuzannaMcclung593 Sep. 21 at 8:50 AM
$DNTH Biotech with phase II data. High risk speculation. Trading near cash value. No pattern.
0 · Reply
topstockalerts
topstockalerts Sep. 19 at 7:55 PM
Several companies saw notable activist-investor moves last week (Sept. 11–17, 2025) via SEC 13D filings. Increases in holdings: Fairmount Funds Management boosted its stake in Dianthus Therapeutics to 4,052,052 shares by buying 600,000 shares at $33 each, now owning 9.9% of the company. Dianthus shares have risen ~67.6% this year. Decreases in holdings: Scorpio Tankers reduced its DHT Holdings stake to 6,157,480 shares, below the 5% reporting threshold; DHT shares are up ~34.3% YTD. TGP GP A sold 3,573,836 Life Time Group Holdings shares, keeping an 8.1% stake; LTH shares have gained ~24.2% YTD. American Industrial Partners sold 1.7M V2X shares, reducing its stake to 26.9% and losing a board seat; VVX shares are up ~20.2% YTD. Access Industries cut Opendoor Technologies holdings to 42,724,914 shares via a 10.87M share sale; OPEN shares have surged ~542.1% YTD. $DNTH $DHT $LTH $OPEN
0 · Reply
JarvisFlow
JarvisFlow Sep. 17 at 1:47 PM
Clear Street has updated their rating for Dianthus Therapeutics ( $DNTH ) to Buy with a price target of 100.
0 · Reply